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Introduction: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a serious event that is
responsible for the progress of the disease, increases in medical costs and high mortality.
Methods: The aim of the present study was to identify AECOPD-specific biomarkers by evaluating the dynamic gene ex-
pression profiling of peripheral blood mononuclear cells (PBMCs) from patients with AECOPD on days 1, 3 and 10 after
hospital admission and to compare the derived data with data from healthy controls or patients with stable COPD.
Results:We found that 14 genes were co–differentially upregulated and 2 downregulated greater than 10-fold in patients
with COPD or AECOPD compared with the healthy individuals. Eight co–differentially upregulated genes and six down-
regulated genes were identified as a panel of AECOPD-specific genes. Downregulation of TCF7 in PBMCs was found to be
associated with the severity of COPD. Dynamic changes of Aminolevulinate-delta-synthase 2 and carbonic anhydrase I
had similar patterns of Digital Evaluation Score System scores and may serve as potential genes of interest during the
course of AECOPD.
Conclusion: Thus, our findings indicate a panel of altered gene expression patterns in PBMCs that can be used as
AECOPD-specific dynamic biomarkers to monitor the course of AECOPD.Introduction
Chronic obstructive pulmonary disease (COPD) is an
inflammation-based syndrome characterized by progres-
sive deterioration of pulmonary function and increasing
airway obstruction [1]. COPD is a major and growing
public health burden, ranking as the fourth leading cause
of death in the world [2]. In China, it is the fourth leading
cause of mortality in urban areas and the third leading
cause in rural areas [3]. Patients with COPD often expe-
rience a sudden deterioration, termed acute exacerbations
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unless otherwise stated.along with a progressive decline in lung function;
AECOPD becomes more frequent and severe when the
severity of disease increases [4,5]. There is a great need for
early and sensitive diagnosis and novel therapeutic targets
for the disease, especially for patients with AECOPD in
whom COPD is diagnosed in the late phase of disease,
when they have significant or irreversible impairment [6].
The progress of COPD is accelerated by the occurrence
of the exacerbation induced by multiple factors, including
infection. AECOPD is a serious event that is related
to decreased health status, increased medical and social
costs and increased mortality [7]. Inflammatory cells
(for example, lymphocytes, monocytes or macrophages,
and their products) could interact with each other or with
structural cells in the airways and the lung parenchymal
and pulmonary vasculature, leading to the worsening of
COPD [8]. Increased numbers of CD8+ lymphocytes were
suggested as one of COPD’s characteristics, being present
only in smokers who develop the disease [9]. Increasedis is an Open Access article distributed under the terms of the Creative
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could attract inflammatory cells from the circulation,
amplify the inflammatory process and induce structural
changes [9].
Peripheral blood mononuclear cells (PBMCs) act as a
critical component in the immune system to fight infection
and adapt to intruders and play an important role in the
development of AECOPD. Gene expression profiles of
PBMCs were found to be disease-specific and associated
with severity [10]. PBMC samples were suggested as easy
to gather and important to the discovery of biomarkers for
diagnosis and therapeutic management of COPD [11,12],
although gene expression changes in lung tissues were
noted to be associated with COPD [13-15]. The aim of
the present study was to determine AECOPD-specific
biomarkers of PBMCs using the concept of clinical
bioinformatics and integrating genomics, bioinformatics,
clinical informatics and systems biology [16-18]. We trans-
lated all clinical measures, including patient complaints,
history, therapies, clinical symptoms and signs, physician’s
examinations, biochemical analyses, imaging profiles,
pathologies and other measurements, into digital format
using a digital evaluation scoring system. PBMCs were
isolated from healthy volunteers and patients with
stable COPD or AECOPD, and we investigated the disease
specificity that we inferred from clinical informatics
analysis to search for COPD- or AECOPD-specific genes












Figure 1 Details of the study design. Healthy volunteers and patients w
exacerbation of COPD (AECOPD) at day 1 (D1), day 3 (D3) or day 10 (D10)
according to the criteria stated in the text. All clinical information was colle
Digital Evaluation Score System. mRNAs of peripheral blood monocytes we
gene expression array and subjected to bioinformatics analysis. AECOPD-spec
and profiles with clinical informatics data.Material and methods
Patient population
The present study was approved by the Ethical Evaluation
Committee of Zhongshan Hospital and designed using a
case–control approach. From among 220 candidates
comprising blood donors (60 healthy controls), inpatients
(80 patients with AECOPD) and outpatients (80 patients
with stable COPD) in Zhongshan Hospital, patients with
AECOPD, patients with stable COPD and healthy controls
matched for age and sex were recruited into the study
between October 2011 and March 2012. The inclusion
criteria for patients with COPD were as follows: (1) forced
expiratory volume in 1 second (FEV1) <80% of predicted
value adjusted for age, weight and height, and (2) an
improvement in FEV1 following bronchodilator inhal-
ation <12% of baseline FEV1. Patients with asthma who
had a persistent airflow obstruction were excluded. Stable
COPD was defined according to American Thoracic
Society/European Respiratory Society consensus criteria
as no requirement for increased treatment above mainten-
ance therapy, other than bronchodilators, for 30 days [1].
AECOPD was the reason for hospital admission and was
characterized as a worsening of the patient’s respiratory
symptoms that was beyond normal day-to-day variations
and led to a change in medication [4,19]. Healthy
controls enrolled were blood donors at Zhongshan
Hospital. Subjects with respiratory diseases, or any
family history of lung disease, were excluded. PBMCsHealth
sCOPD











ith stable chronic obstructive pulmonary disease (sCOPD) or acute
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cted and transferred into the clinical informatics database using the
re harvested, and gene expression profiles were measured by human
ific biomarkers were selected by integrating gene functional networks
Table 1 Clinical phenotypes of healthy controls, patients with stable chronic obstructive pulmonary disease and
patients with acute exacerbation of chronic obstructive pulmonary diseasea
Groups Subject no. Age (yr) Smoking status FEV1/FVC% FEV1/pred% Goddard emphysema score
Control 1 56 Nonsmoker 75 85 0
2 53 Nonsmoker 80 87 0
3 62 Nonsmoker 77 91 0
4 68 Nonsmoker 81 83 0
5 58 Nonsmoker 79 81 0
6 67 Nonsmoker 76 90 0
Mean ± SE 60.7 ± 2.5 78.0 ± 1.0 86.2 ± 1.6 0.0 ± 0.0
Stable COPD 1 71 Ex-smoker 57 47 10
2 75 Ex-smoker 46 66 6
3 61 Ex-smoker 46 47 8
4 57 Ex-smoker 38 29 12
5 59 Ex-smoker 67 66 7
6 53 Ex-smoker 29 36 11
Mean ± SE 62.7 ± 3.5 47.2 ± 5.5 48.5 ± 6.2 9.0 ± 1.0
AECOPD 1 77 Ex-smoker 40 42 10
2 72 Ex-smoker 36 27 11
3 65 Ex-smoker 28 33 16
4 56 Ex-smoker 48 61 6
5 61 Ex-smoker 69 55 4
6 67 Ex-smoker 56 60 8
Mean ± SE 66.3 ± 3.1 46.2 ± 6.0 46.3 ± 5.9 9.2 ± 1.7
aAECOPD, Acute exacerbation of chronic obstructive pulmonary disease; COPD, Chronic obstructive pulmonary disease; FEV1, Forced expiratory volume in
1 second; FVC, Forced vital capacity; pred, Prediction. Data represent information gathered on days 1, 3 and 10 of hospital admission.
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with stable COPD, as well as from patients with AECOPD,
on the admission day and 3 and 10 days after the
admission. Informed consent was given by the subjects
themselves before they underwent lung function tests,
high-resolution computed tomography and blood collec-
tion. The time points used in the present study were
selected on the basis of our previous study for collecting
plasma samples from healthy controls and from patientsTable 2 Digital evaluation score system scoresa
DESS scores
Patient no. Control Stable COPD AE-1 AE-3 AE-10
1 0 30 100 78 43
2 4 27 81 66 46
3 8 35 86 76 36
4 4 55 70 51 30
5 3 38 80 71 35
6 0 47 97 81 30
Mean ± SE 3.2 ± 1.2 38.7 ± 4.3 85.7 ± 4.6 70.5 ± 4.5 36.7 ± 2.7
aAE-1, Day 1 of hospital admission; AE-3, Day 3 of hospital admission; AE-10,
Day 10 of hospital admission; COPD, Chronic obstructive pulmonary disease;
DESS, Digital evaluation score system.with stable COPD or AECOPD. The details of the study
design are explained in Figure 1.
Digital evaluation score system
The Digital Evaluation Score System (DESS) is a score
index used to translate clinical descriptions and informa-
tion into clinical informatics, as described previously
[20]. Using this instrument, we took into account patient
symptoms and signs, biochemical analyses and clinical
imaging for patients with stable COPD or AECOPD.
Briefly, for the assessment of severity, each component
was assigned a score of 0, 1, 2 or 4. The score of 4 as
the maximum value indicates far above normal range or
much severer condition, and 0 as the minimum value
indicates within normal physiological range. After com-
piling patient data, we added the points for each variable.
The DESS scores ranged from 0 to 256 points, with a
higher score indicating a severer condition. Patients
were scored on the day when their blood samples were
collected.
Isolation of PBMC RNA
PBMCs were isolated by using BD Vacutainer CPT cell




















































































Figure 2 Scatterplots showing variations in gene expression profiles. Scatterplots of peripheral blood monocytes between patients with
stable chronic obstructive pulmonary disease (Stable COPD) (A), acute exacerbation of chronic obstructive pulmonary disease at day 1 of hospital
admission (AECOPD-D1) (B), AECOPD at day 3 of hospital admission (AECOPD-D3) (C) or AECOPD at day 10 of hospital admission (AECOPD-D10)
(D) compared with healthy controls. Scatterplots also illustrate variations between AECOPD-D1 (E), AECOPD-D3 (F) or AECOPD-D10 (G) and stable
COPD; between AECOPD-D3 (H) or AECOPD-D10 (I) with AECOPD-D1; and between AECOPD-D3 and AECOPD-D10 (J).
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Approximately 4 ml of whole blood was collected from
each subject. Following centrifugation, cells were lysed
for RNA isolation. DNase-free total RNA preparation
was performed using TRIzol reagent (Life Technologies,
Carlsbad, CA, USA) and the RNeasy kit (QIAGEN,
Valencia, CA, USA) according to the manufacturers’Table 3 Genes upregulated in peripheral blood
mononuclear cellsa
Fold changes in upregulated genes (n)
Comparisons >2 >5 >8 >10 >15 >20 >30 >50 >100
Stable vs Con 4,508 671 217 145 49 27 9 1 0
AE-1 vs Con 3,899 734 334 221 136 86 40 18 3
AE-3 vs Con 4,167 742 358 259 149 97 51 17 5
AE-10 vs Con 3,488 677 331 238 116 74 35 10 1
AE-1 vs Stable 4,067 389 135 80 36 21 9 3 1
AE-3 vs Stable 5,063 620 221 146 56 24 10 1 0
AE-10 vs Stable 5,451 534 178 117 56 33 14 1 0
AE-3 vs AE-1 586 8 2 2 0 0 0 0 0
AE-10 vs AE-1 1,735 164 55 26 10 4 1 0 0
AE-10 vs AE-3 1,706 156 49 29 2 2 1 0 0
aData are number of upregulated genes expressed in peripheral blood
mononuclear cells of healthy controls (Con) or of patients with stable chronic
obstructive pulmonary disease (Stable) or acute exacerbation of chronic
obstructive pulmonary disease on hospital admission day 1 (AE-1), day 3
(AE-3) and day 10 (AE-10).recommendations. RNA concentrations were deter-
mined by using a NanoDrop ND-1000 spectrophotom-
eter (NanoDrop, Wilmington, DE, USA). RNA quality
was assessed on an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA), and samples with
an RNA integrity number >6.0 were used.
Microarray analysis
The Human 12×135K Gene Expression Array (Roche
NimbleGen Systems, Madison, WI, USA), with about
45,000+ human genes and transcripts represented with
public domain annotations, was applied for this study.
Sample labeling and array hybridization were performed
according to the one-color microarray-based gene ex-
pression analysis protocol (Roche NimbleGen Systems).
Double-stranded cDNA (ds-cDNA) was synthesized from
5 μg of total RNA using an Invitrogen SuperScript reverse
transcriptase ds-cDNA synthesis kit (Life Technologies)
in the presence of 100 pmol oligo(dT) primers. ds-cDNA
was cleaned and labeled in accordance with the
NimbleGen gene expression analysis protocol. Briefly,
ds-cDNA was incubated with 4 μg of RNase A at 37°C
for 10 minutes and cleaned using phenol:chloroform:
isoamyl alcohol, followed by ice-cold absolute ethanol
precipitation. The purified cDNA was quantified using
the NanoDrop ND-1000 spectrophotometer. For Cy3
labeling of cDNA, the NimbleGen one-color DNA
labeling kit was used according to the manufacturer’s
Table 4 Genes upregulated >30-fold in peripheral blood mononuclear cellsa
Stable vs control AE-1 vs control AE-3 vs control AE-10 vs control
Fold changes Genes Fold changes Genes Fold changes Genes Fold changes Genes
31.7 REXO1L2P 30.3 HP 30.1 FOS 30.8 EMP2
33.0 DEFA1 30.5 LOC152573 30.6 BPIL1 31.0 SEPP1
33.3 DUB3 31.2 INHBA 31.0 ARG1 31.0 FOLR1
37.2 LOC402207 31.4 COL6A3 31.6 N/A 31.1 GPX3
37.3 DUB3 32.4 MPO 31.9 LOC152573 31.2 SFTPB
40.5 LOC402110 32.6 ELF3 32.5 COL6A3 31.4 S100A14
43.1 LOC653600 34.4 CLDN4 32.9 TIMP3 33.1 FOLR1
43.5 N/A 34.9 DCN 33.5 FOS 33.4 CDH5
50.7 MGC45438 35.7 CTGF 34.4 KRT19 34.9 CAV1
35.7 MMP2 34.7 INHBA 35.4 DLC1
36.2 MFAP4 35.2 HP 35.6 FOSB
37.1 EPB42 35.6 CD177 36.1 KRT19
37.2 H19 36.5 LCN2 36.4 SUSD2
37.3 ATP1B1 36.9 CTGF 36.9 FN1
37.5 INHBA 37.9 MMP8 37.2 ADH1C
38.0 AZU1 38.3 ORM1 37.2 RNASE1
38.5 LCN2 38.8 ELF3 37.3 IL1RL1
39.6 CEACAM8 38.9 DCN 41.1 FOLR1
40.3 CALCA 39.0 CTSG 41.3 DHCR24
41.4 LOC387763 39.1 CLDN4 41.3 LOC387763
42.2 CEACAM3 39.3 CALCA 42.0 ADH1B
45.9 UNQ473 40.0 DCN 43.6 LAMA3
54.0 BPIL1 40.1 FOSB 45.0 GPX3
56.2 FN1 41.1 ATP1B1 47.9 DCN
56.7 CEACAM5 41.6 MFAP4 49.1 EPAS1
58.4 MMP8 41.8 FN1 50.9 CNN3
65.0 CALCA 42.0 MMP2 51.5 DCN
66.3 BPI 42.0 GPR97 54.5 LOC653509
68.7 DEFA1 42.2 INHBA 56.2 CXCL2
72.3 COL1A2 45.5 AZU1 58.2 MGC45438
77.2 CA1 46.0 BPI 58.5 CYP4B1
80.2 PLUNC 46.4 LOC387763 59.3 CTGF
83.0 CEACAM1 46.6 MPO 75.8 GPRC5A
83.9 DEFA4 50.0 HP 88.9 TIMP3
85.0 COL3A1 50.7 ORM2 149.5 MFAP4
96.1 DEFA1 53.1 UNQ473
99.4 CEACAM5 57.8 AQP9
101.2 CEACAM1 59.6 CEACAM5
115.8 LOC653600 59.6 BPIL1
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aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.
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protocol. One microgram of ds-cDNA was incubated
for 10 minutes at 98°C with 1 optical density of
Cy3-9mer primer. Next, 100 pmol of deoxynucleoside
triphosphates and 100 U of the Klenow fragment
(New England Biolabs, Ipswich, MA, USA) were
added, and the mix was incubated at 37°C for 2 hours.
The reaction was stopped by adding 0.1 vol of 0.5 M
ethylenediaminetetraacetic acid, and the labeled ds-cDNA
was purified by isopropanol/ethanol precipitation. Micro-
arrays were hybridized at 42°C for 16 to 20 hours with
4 μg of Cy3-labeled ds-cDNA in NimbleGen hybridization
buffer/hybridization component A in a hybridization cham-
ber. Following hybridization, washing was performed using
the NimbleGen wash buffer kit. After being washed in an
ozone-free environment, the slides were scanned using an
Axon GenePix 4000B microarray scanner (Molecular
Devices, Sunnyvale, CA, USA).
Data analysis
For clinical data, all values were expressed as mean ± SE.
Analyses were performed using SPSS software (SPSS
18.0; SPSS, Chicago, IL, USA). For microarray analysis,
slides were scanned at 5 μm/pixel resolution using the
Axon GenePix 4000B microarray scanner piloted by
GenePix Pro 6.0 software (Molecular Devices). Scanned
images (in TIFF file format) were then imported into
NimbleScan software (version 2.5) files for grid
alignment and expression data analysis. Expression
data were normalized through quantile normalization
and the Robust Multi-array Average (RMA) algorithm
included in the NimbleScan software. The probe-level
(*_norm_RMA.pair) files and gene-level (*_RMA.calls)
files were generated after normalization. All gene-level
files were imported into GeneSpring GX software
(version 11.5.1; Agilent Technologies) for further analysis.
Differentially expressed genes between two samples were
identified by fold change filtering. Hierarchical clustering
was performed using the GeneSpring GX software.
Gene Ontology (GO) database analysis and pathwayanalysis were performed using the standard enrichment
computation method. The GO database covers three
domains: biological process, cellular component and
molecular function. Fisher’s exact test was used to
find more overlaps between the descriptive list and
the GO annotation list than would be expected by
chance. The P-value denoted the significance of GO
term enrichment in the descriptive genes. The gene
expression data are publicly available in the Gene
Expression Omnibus database [GEO:GSE60399] [21].
Results
Clinical informatics analysis
Clinical phenotypes are described in Table 1, including
age, sex, smoking status, lung function test results and
emphysema scores of the subjects. Control subjects
were nonsmokers, and patients with stable COPD or
AECOPD were ex-smokers. Because of the severity of
disease, lung function tests were not performed at the
onset of AECOPD; however, the baseline FEV1/forced
vital capacity (FVC%) and FEV1/predicted percentage
of patients with AECOPD were similar to those of
patients with stable COPD. In addition, there was no
significant difference in the extent of emphysema between
patients with stable COPD and those with AECOPD
(P = 0.47). DESS scores of subjects from each group are
shown in Additional file 1. DESS values of patients with
stable COPD or AECOPD were significantly higher than
those of control subjects (P < 0.01), as shown in Table 2.
DESS scores represented the severity of COPD and
declined as the patient’s condition improved. DESS
values of patients with AECOPD on day 1 of hospital
admission (AE-1) were significantly higher than those on
day 3 (AE-3) and day 10 (AE-10) (P < 0.05 and P < 0.01,
respectively) (Table 2).
Gene expression profiles
The quality of the genetic data obtained after filtering and
the distribution of data sets were assessed and visualized
by creating box plots, which showed that there were no
Table 5 Genes upregulated between 20- and 30-fold in peripheral blood mononuclear cells of patients with stable
COPD or AECOPD compared with healthy control subjectsa
Stable vs control AE-1 vs control AE-3 vs control AE-10 vs control
Fold changes Genes Fold changes Gene Fold changes Genes Fold changes Genes
20.1 P8 20.3 PLAU 20.0 ALPL 20.3 SCNN1A
20.1 REXO1L5P 21.0 COL6A3 20.1 MUC1 20.4 MGC45438
20.2 UNQ473 21.1 SLC25A37 20.2 SPDEF 20.7 FBLN1
20.2 DEFA1 21.1 HIG2 20.3 HIG2 20.7 CLDN4
20.5 LOC440015 21.2 GPRC5A 20.4 KLK11 20.9 SFTPA2
21.1 LOC391749 21.2 CFB 20.4 MGP 21.0 FKBP9
21.3 MGC45438 21.3 LTF 20.4 GPR109A 21.1 FAM107A
21.7 RP11-146D12.2 21.4 VSIG4 21.0 LOC653342 21.3 N/A
22.0 LOC399839 21.7 FOSB 21.1 CFB 21.4 C10orf10
22.9 SPDEF 21.9 SLC25A37 21.3 P8 21.5 SELENBP1
23.0 CLDN4 22.0 ARG1 21.8 PBEF1 21.6 ANXA3
24.7 LOC349196 22.0 SPDEF 21.9 S100P 21.6 IFI27
25.3 STAC2 22.2 LTF 21.9 MS4A3 21.8 C1QC
25.8 REXO1L3P 22.3 FOS 22.4 COL6A3 21.9 SEPP1
26.3 SCGB3A1 22.6 FAM46C 23.1 MANSC1 22.0 KLK11
26.9 RNASE1 22.6 ISLR 23.2 COL1A2 22.1 P8
27.0 AZGP1 22.6 COL1A2 23.2 GCA 22.1 LOC653723
29.5 H19 22.8 ATP1B1 23.3 LTBP2 22.5 LOC391359
23.8 SCNN1A 23.9 CHI3L1 22.7 LAMB2
23.8 SERPINE1 24.0 TMC5 22.8 AQP1
23.8 EPB42 24.2 CD24 24.0 C9orf61
23.8 C1QC 24.2 HP 24.1 C4BPA
23.9 RGS1 24.3 ISLR 24.2 LTBP2
23.9 ORM2 24.3 SIX1 24.3 UNQ473
24.1 COL5A1 24.5 APOE 24.5 TMEM139
24.5 MS4A3 24.6 COL3A1 24.6 N/A
25.6 CD177 24.6 LOC646309 25.7 OLFML3
25.6 APOE 24.7 CEACAM3 25.9 SNF1LK
26.4 C20orf114 24.9 AATK 25.9 A2M
26.6 BPIL1 25.3 LTF 26.4 FXYD3
27.1 CTSG 25.4 ALPL 27.0 HP
27.4 FOS 25.6 ACSL1 27.1 N/A
27.6 ALAS2 26.2 CEACAM6 27.4 LOC653509
28.0 INHBA 26.3 COL5A1 28.0 LDB2
28.0 TIMP3 26.4 KLK11 28.0 OLFML3
28.1 COL3A1 26.7 PRTN3 28.5 SFTPA1
28.1 SLC4A1 26.9 RGS1 28.6 MUC1
28.2 KLK11 27.3 KCNJ15 29.6 HSPA12B
28.2 LOC653492 27.4 CAMP 29.8 MFAP4
28.5 LOC203510 27.6 PLAU
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Table 5 Genes upregulated between 20- and 30-fold in peripheral blood mononuclear cells of patients with stable
COPD or AECOPD compared with healthy control subjectsa (Continued)
28.7 CEACAM3 27.8 LTF
28.8 DCN 27.9 ANXA3
28.9 CEACAM1 28.0 H19
29.0 CEACAM6 28.0 SERPINE1
29.3 SELENBP1 28.1 LTF
29.7 KRT19 28.3 INHBA
aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.
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among the groups (see Additional file 2: Figure S1).
The variation or reproducibility of gene expression
between arrays of different groups was visualized and
assessed by creating scatterplots, which are shown in
Figure 2. There was a significant variation in gene arrays
between healthy controls and patients with stable
COPD or AECOPD (Figures 2A to 2D) and between
patients with stable COPD and AECOPD (Figures 2E
to 2G). The variation in gene array data at AE-1 and
AE-3 was significantly different from that at AE-10
(Figures 2I and 2J), whereas there was no difference
between AE-1 and AE-3 (Figure 2H). The results of hier-
archical clustering showed gene expression profiles similar
to those revealed by the scatterplots shown in Figure S2 of
Additional file 2.
To identify differentially expressed genes, a fold change
filtering between each group pair was performed with a
threshold fold change ≥2.0. There were ten comparison
pairs with information for fold changes and regulation (that
is, SEQ-ID, log fold change, log or absolute fold change, or
regulation), normalized intensities or annotations (that is,
GENE_NAME, synonyms, description, NCBI_GENE_ID,
chromosome, GO, UniGene ID, The Institute of Genomic
Research Database-TDB (TIGRID) or Ensembl ID), as
shown in Additional file 3. Table 3 shows the number of
genes overexpressed more than twofold, (for example,
4,508, 3,899, 4,167 and 3,488 genes of stable, AE-1, AE-3
and AE-10, respectively, above controls; 4,067, 5,063 or
5,451 genes of AE-1, AE-3 and AE-10, respectively,
above stable COPD; 586 genes of AE-3 above AE-1;
and 1,735 and 1,706 genes of AE-10, respectively,
above AE-1 and AE-3). Tables 4, 5 and 6, respect-
ively, list the genes overexpressed (above controls) in
PBMCs from patients with stable COPD, AE-1, AE-3
or AE-10 by more than 30-fold (Table 4), between
20- and 30-fold (Table 5) and between 15- and 20-
fold (Table 6). Tables 7, 8 and 9 list the genes overex-
pressed (above patients with stable COPD) in PBMCs
from patients with AE-1, AE-3 or AE-10 by more
than 30-fold (Table 7), between 20- and 30-fold (Table 8)and between 15- and 20-fold. Table 10 presents up-
regulated genes in PBMCs of patients at AE-1, AE-3
or AE-10.
Table 11 lists the number of genes downregulated more
than twofold, including 4,516, 2,975, 3,426 and 2,798
genes of PBMCs from patients with stable COPD on
AE-1, AE-3 and AE-10, respectively, below controls; 3,207,
4,510 and 5288 genes on AE-1, AE-3 and AE-10, respect-
ively, below stable COPD; 598 genes from AE-3 below
AE-1; and 2,162 and 1,918 genes from AE-10 below those
from AE-1 and AE-3, respectively. Downregulated genes
of PBMCs from patients with stable COPD, AE-1, AE-3 or
AE-10 greater than tenfold, between 10- and 8-fold or
between 8- and 6-fold below healthy control subjects are
listed in Tables 12, 13 and 14, respectively. Downregulated
genes of PBMCs from patients at AE-1, AE-3 or AE-10
compared to stable COPD, or among patients with
AECOPD, are shown in Tables 15 and 16.
COPD-specific genes
To search for COPD-specific genes, co–differentially
expressed genes of PBMCs from patients with stable
COPD or AECOPD were compared with those from
control subjects (listed in Additional file 4). There
were five groups and four comparison pairs with
information regarding fold changes and regulation
(that is, SEQ-ID, fold change, log or absolute fold
change, or regulation), normalized intensities or annota-
tions (that is, GENE_NAME, synonyms, description,
NCBI_GENE_ID, chromosome, GO, UniGene ID,
TIGRID or Ensembl ID). Seventy-nine genes were upregu-
lated and 23 genes downregulated in PBMCs from
patients with COPD, including both stable COPD
and AECOPD, as compared to the healthy control
subjects, as shown in Table 17. Of them, 14 genes
were upregulated and 2 were downregulated more than
tenfold, as compared to control subjects, including
carcinoembryonic antigen–related cell adhesion molecule
1, collagen type VIα3(VI), collagen type I(α)2(I), nucleolar
protein 3 (apoptosis repressor with CARD domain),
melanophilin, cell surface–associated mucin 1, nuclear
Table 6 Genes upregulated between 15- and 20-fold in peripheral blood mononuclear cells of patients with stable
COPD or AECOPD compared with healthy control subjectsa
Stable vs control AE-1 vs control AE-3 vs control AE-10 vs control
Fold changes Genes Fold changes Genes Fold changes Genes Fold changes Genes
15.2 LOC645558 15.0 CNN3 15.0 GPR109B 15.0 USP54
15.7 N/A 15.0 GPT2 15.0 LOC653492 15.0 MGC45438
15.9 LOC653455 15.1 ORM1 15.2 RNASE1 15.2 SLCO2A1
15.9 DUX4 15.1 LOC402110 15.3 FN1 15.3 AGER
16.1 LOC653768 15.1 MDK 15.5 ACSL1 15.3 FLJ11259
16.5 RAB17 15.2 ELF3 15.5 CDH5 15.5 CLEC3B
16.6 LOC653541 15.2 PSG8 15.6 FOLR3 15.8 ADCY4
16.6 LOC391763 15.3 SLC25A37 15.8 PVRL2 16.0 FN1
16.7 LOC642286 15.4 FKBP9 15.9 KRT19 16.1 HP
16.7 S100A14 15.5 C1QB 15.9 MDK 16.1 CKB
16.7 NBPF9 15.6 BPGM 16.0 APOC1 16.1 CYP4B1
16.9 PSG8 15.7 AQP9 16.3 NOL3 16.2 RARRES2
17.0 REXO1L6P 15.7 LOC402207 16.3 ATP1B1 16.3 TSPAN1
17.0 MLPH 15.7 PSG11 16.4 TMC4 16.6 SDC4
17.1 FAM90A7 16.0 KLK11 16.4 VEGF 16.7 ERG
17.4 LOC401650 16.2 KIAA0703 16.6 SPAG4 16.8 LOC653107
17.8 DUB3 16.2 IGFBP5 16.8 LIF 17.2 RAB25
17.9 MGC45438 16.2 IGFBP3 16.8 CCDC80 17.2 COL1A2
18.9 COL3A1 16.2 N/A 16.9 CEACAM3 17.3 DCN
19.1 LOC645732 16.2 SLC25A37 16.9 IGFBP3 17.5 TSPAN13
19.8 LOC392188 16.3 SIX1 17.1 CXCL2 17.6 HSD17B6
20.0 MUC1 16.3 LOC645009 17.2 FKBP9 17.8 RHOB
16.4 C1QA 17.2 CEACAM1 17.9 KRT19
16.5 UBD 17.7 ELF3 18.0 AQP9
16.6 LOC653342 17.7 CNN3 18.2 FOLR1
17.0 GPR97 17.8 PGLYRP1 18.2 IL1RL1
17.1 COL1A1 17.9 KRT23 18.2 SERPING1
17.3 ALPL 18.1 SLC44A4 18.3 MGC35295
17.4 FBLN1 18.1 SCNN1A 18.4 FLJ43663
17.5 HIG2 18.4 FBLN1 18.6 TGM2
17.7 COL8A1 18.5 HPR 18.6 ADH1C
17.9 TMC5 18.6 SYT7 18.7 KIAA1026
18.1 LTBP2 18.6 CEACAM8 19.1 DKFZP686A01247
18.4 SLC25A37 18.8 C1R 19.2 CCDC48
18.7 CEACAM3 18.8 COL1A1 19.2 ANKRD25
18.9 MPO 18.9 COL8A1 19.3 DMBT1
19.0 CD24 18.9 C1QC 19.4 MALL
19.0 CHI3L1 18.9 SFRP2 19.5 ANXA8
19.0 DCN 19.0 HIG2 19.5 SPRY4
19.1 P8 19.2 C1QB 19.7 ELF3
19.1 CEACAM6 19.2 GPRC5A 19.9 EHD2
19.1 ACSL1 19.3 MMP25 20.0 DCN
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Table 6 Genes upregulated between 15- and 20-fold in peripheral blood mononuclear cells of patients with stable
COPD or AECOPD compared with healthy control subjectsa (Continued)
19.5 PRTN3 19.3 UBD
19.5 LIF 19.3 GADD45A
19.6 LTF 19.4 ISLR
19.7 ANXA3 19.5 ORM1
19.7 C1R 19.5 C20orf114
19.7 MUC1 19.5 LOC203510
19.8 PSG4 19.6 DCN
19.9 HP 19.7 FN1
19.8 DAAM2
19.9 FOLR3
aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3
(AE-3) and day 10 (AE-10) of hospital admission, as compared to healthy controls.
Table 8 Genes upregulated between 20- and 30-fold in
peripheral blood mononuclear cells of patients with
AECOPD compared to patients with stable COPDa
AE-1 vs stable AE-3 vs stable AE-10 vs stable
Fold Genes Fold Genes Fold Genes
Wu et al. Critical Care  (2014) 18:508 Page 10 of 27protein 1, chemokine (C-X-C motif) ligand 17, claudin 4,
ribonuclease 1, imprinted maternally expressed transcript,
defensin α1, transcription factor CP2-like 1 and sterol
carrier protein 2 (SCP2).
AECOPD-specific genes
To search for AECOPD-specific genes, co–differentially
expressed genes of PBMCs from patients with AECOPD
on days 1, 3 and 10 were compared to those from either
patients with stable COPD or healthy control subjects
(listed in Additional file 4). There were five groups andTable 7 Genes upregulated >30-fold in peripheral blood
mononuclear cells of patients with AECOPD compared to
patients with stable COPDa








37.3 MMP8 33.2 LOC646309 30.0 CCDC48
37.6 CEACAM5 34.7 SERPINE1 31.9 LOC653509
38.6 PLUNC 34.9 FOS 32.0 EPAS1
39.4 BPIL1 37.6 CYR61 32.2 CDH5
40.3 CYR61 39.5 CEACAM5 34.4 CLDN5
45.4 CEACAM5 39.6 PLUNC 36.3 SEPP1
55.2 CALCA 40.1 ARG1 38.7 CAV1
56.0 VSIG4 43.5 BPIL1 39.2 CYR61
103.9 CA1 46.0 CEACAM5 42.1 ADH1B





aData are from patients with patients with acute exacerbation of chronic
obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10
(AE-10) of hospital admission, as compared to patients with stable chronic
obstructive pulmonary disease (Stable).six comparison pairs with information regarding fold
changes and regulation (that is, SEQ-ID, fold change,
log or absolute fold change, or regulation), normalized
intensities or annotations (that is, GENE_NAME, syno-
nyms, description, NCBI_GENE_ID, chromosome, GO,changes changes changes
20.1 MS4A3 20.5 GPR97 20.3 TIMP3
21.0 CEACAM6 20.6 ALPL 20.3 SLC6A4
21.1 SLC25A37 20.7 MTHFS 20.4 SFTPA2
21.2 DCN 21.0 FLJ32028 20.6 AKAP2
22.4 SPP1 21.4 ADM 20.7 DST
24.0 TCN1 23.3 ACSL1 21.2 TCF21
24.7 BPIL1 23.3 DCN 21.5 ADH1C
26.4 SLC25A37 24.3 MMP8 21.6 SLIT3
26.6 CTGF 24.5 TCN1 21.7 C9orf61
28.5 ARG1 25.3 FOS 22.5 FOSB
28.6 FOS 25.3 FOSB 25.5 MFAP4
29.5 SERPINE1 27.5 CTGF 26.0 GPX3
28.3 BPIL1 26.5 DCN






aData are from patients with patients with acute exacerbation of chronic
obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10
(AE-10) of hospital admission, as compared to patients with stable chronic
obstructive pulmonary disease (Stable).
Table 9 Genes upregulated between 15- and 20-fold in
peripheral blood mononuclear cells of patients with
AECOPD compared to patients with stable COPDa








15.6 ADM 15.2 LOC387763 15.0 VSIG4
15.8 DEFA4 15.2 MMP25 15.6 IL1RL1
16.2 DEFA4 15.3 USP15 15.8 PZP
16.2 C1R 15.5 C1R 16.0 LDB2
16.9 GPNMB 15.8 KCNJ15 16.2 FLJ43663
17.2 DCN 15.9 GADD45A 16.5 N/A
17.3 FAM46C 15.9 LRRC4 16.6 CD55
17.6 ALAS2 16.3 GLT1D1 16.8 CXCL2
17.6 CALCA 16.4 CD55 16.9 IL1RL1
17.9 GPNMB 16.5 CEACAM6 17.0 RHOB
18.2 DUSP1 16.6 SPP1 17.1 DLC1
18.2 CEACAM6 16.7 SLC25A37 17.2 VIPR1
18.2 SLC25A37 17.1 ORM1 17.2 CRYAB
18.7 FOS 17.2 CALCA 17.8 CNN3
18.9 SLC25A37 17.3 DUSP1 18.1 DCN
17.5 CD177 18.1 IFI27
17.6 GPNMB 18.2 SLIT2
17.7 MS4A3 18.3 RASIP1
17.8 DCN 18.8 MFAP4
17.8 GPR109A 19.0 CAMK2N1
17.9 BASP1 19.0 CD55
17.9 IL8RB 19.5 AGER










aData are from patients with patients with acute exacerbation of chronic
obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10
(AE-10) of hospital admission, as compared to patients with stable chronic
obstructive pulmonary disease (Stable).
Table 10 Genes upregulated more than fivefold in
peripheral blood mononuclear cells of patients with
AECOPDa








5.1 TMEM50A 10.3 SUSD2 10.1 SLCO2A1
5.2 BCL2A1 10.6 TCF21 10.1 OAS3
5.3 C6orf32 10.6 FOLR1 10.1 C4BPA
6.0 PI3 10.7 C9orf61 10.2 DMBT1
7.0 KCNJ15 10.9 LOC653107 10.4 VSIG2
7.6 CISH 11.3 AGER 10.4 LOC653107
10.4 CISH 12.0 SLIT2 10.5 ITLN2
10.7 CISH 12.7 ITLN2 10.7 CX3CR1
12.9 FLRT3 10.7 MSLN
13.1 VIPR1 10.8 SOCS2
13.2 SOCS2 10.9 LOC653107
13.3 IL1RL1 11.7 FOLR1
13.4 LOC653107 11.7 GPX3
13.8 C4BPA 11.8 CLIC5
14.4 CYP4B1 11.8 SLIT2
14.4 LAMA3 11.9 LOC653107
15.1 CYP4B1 12.1 AQP1
15.2 ADH1C 12.6 LOC653509
15.7 MGC35295 12.6 ADH1C
15.8 GPX3 12.7 ADH1C
17.0 IL1RL1 12.8 ADH1B
17.9 MSLN 12.9 LAMA3
20.0 ADH1C 13.6 IL1RL1
22.4 ADH1B 13.6 CYP4B1
24.5 SLC6A4 13.9 FAM107A




aData are from day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission.
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with both patients with stable COPD and healthy
control subjects, 58 genes were upregulated more than
fivefold and 238 downregulated more than twofold in
patients with AECOPD. Of them, eight upregulated
(more than tenfold) and eight downregulated (more
than threefold) genes are listed in Table 18. Thesegenes include FBJ murine osteosarcoma viral oncogene
homologue (FOS); interferon α-inducible protein 27
(IFI27); cysteine-rich angiogenic inducer 61 (CYR61),
connective tissue growth factor (CTGF); G protein–coupled
receptor family C group 5 member A (GPRC5A); FBJ
murine osteosarcoma viral oncogene homologue B (FOSB);
decorin (DCN); hypothetical LOC387763 (LOC387763);
killer cell immunoglobulin-like receptor, two domains,
short cytoplasmic tail, 2 (KIR2DS2); SH2 domain contain-
ing 1B (SH2D1B); CD8b molecule (CD8B); olfactory recep-
tor family 2, subfamily W, member 5 (OR2W5); fibroblast
Table 11 Number of downregulated genes in peripheral blood mononuclear cells of healthy control subjects, patients
with stable COPD and patients with AECOPDa
Fold changes in upregulated genes (n)
Compared pairs >2 >5 >6 >8 >10 >15 >20 >30 >50 >100
Stable vs Con 4,516 135 55 9 4 2 1 0 0 0
AE-1 vs Con 2,975 182 107 47 22 7 4 1 0 0
AE-3 vs Con 3,426 225 149 65 35 11 5 2 0 0
AE-10 vs Con 2,798 124 73 31 16 2 1 1 0 0
AE-1 vs Stable 3,207 33 16 4 4 2 0 0 0 0
AE-3 vs Stable 4,510 125 71 21 8 3 1 0 0 0
AE-10 vs Stable 5,288 445 236 97 49 20 8 3 0 0
AE-3 vs AE-1 598 32 23 17 5 3 2 0 0 0
AE-10 vs AE-1 2,162 261 168 82 43 21 14 10 5 1
AE-10 vs AE-3 1,918 192 130 66 36 15 9 6 4 0
aData are from controls (Con) or patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary
disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission.
Wu et al. Critical Care  (2014) 18:508 Page 12 of 27growth factor binding protein 2 (FGF2); and transcription
factor 7 (TCF7).
Dynamic change in gene expression in patients with
AECOPD
Dynamic changes (down–down, down–up, up–down
and up–up) of co–differentially expressed genes of
PBMCs from patients with AECOPD are listed in
Additional file 4, including fold changes and regulation
(that is, SEQ-ID, fold change, log or absolute fold
change, or regulation), normalized intensities or anno-
tations (that is, GENE_NAME, synonyms, description,
NCBI_GENE_ID, chromosome, GO, UniGene ID,
TIGRID or Ensembl ID). Table 19 shows the dynamic
changes in the patterns of down–down (52 genes),
down–up (131 genes), up–down (238 genes) and up–up (8
genes) more than twofold, as compared with the gene
expression on the previous day. The major genes of PBMCs
from patients with AECOPD were aminolevulinate, delta-,
synthase 2 (ALAS2), erythrocyte membrane protein band
4.2 (EPB42) and carbonic anhydrase I (CA1) in a down–
down pattern; selenium-binding protein 1 (SELENBP1) and
myosin heavy chain 9, non-muscle (MYH9), in a down–up
pattern; HLA complex group 27 (HCG27), BCL2-related
protein A1 (BCL2A1), G protein–coupled receptors 109A
and 109B (GPR109A and GPR109B) in an up–down
pattern; and zeta protein kinase C (PRKCZ), ATP-binding
cassette, subfamily A, member 8 (ABCA8), and folate
receptor 1 (adult) (FOLR1) in an up–up pattern (Table 19).
Levels of genes from patients with AECOPD were also
compared with those from patients with stable COPD, as
shown in Figure 3, where positive or negative values indi-
cate up- or downregulation as compared with those from
patients with stable COPD. When correlated with DESS,
ALAS2 and CA1 had similar patterns of change with DESS.Gene ontology analysis and pathway analysis
Within ten comparison pairs, up- or downregulated
genes mainly involved in the biological process are
shown in Figures S3 and S4 of Additional file 2, those in
cellular components are shown in Figures S5 and S6 of
Additional file 2 and those in molecular functions
are shown in Figures S7 and S8 of Additional file 2.
Additional file 5 lists gene numbers for ten comparison
pairs with certain GO terms and different ranges of
enrichment scores.
In the biological process, COPD-specific upregulated
genes were involved mainly in peptide cross-linking,
blood vessel development, biological adhesion or cell
adhesion (Figure 4A). COPD-specific downregulated
genes were involved mainly in T cell receptor signaling
pathways, antigen receptor–mediated signaling pathways,
immune response–activating cell surface receptor
signaling pathways or steroid biosynthetic process
(Figure 4B). AECOPD-specific genes upregulated in
response to organic substance, response to wounding,
multicellular organismal process or response to chemical
stimulus are shown in Figure 4C. AECOPD-specific
downregulated genes were involved mainly in the
regulation of immune response and the immune system
process or in the immune response and immune sys-
tem process themselves (Figure 4D). In the cellular
component, COPD-specific upregulated genes were
involved mainly in the extracellular region, the extracellu-
lar matrix part, the proteinaceous extracellular matrix or
the extracellular matrix (Figure 5A). COPD-specific
downregulated genes were involved mainly in the major
histocompatibility complex class II (MHC II) protein
complex, microbody lumen, peroxisomal matrix or MHC
II protein complex (Figure 5B). AECOPD-specific upregu-
lated genes were involved mainly in the extracellular
Table 12 Genes downregulated more than tenfold in peripheral blood mononuclear cells of patients with stable COPD
or AECOPD compared to healthy control subjectsa
Stable vs Con AE-1 vs Con AE-3 vs Con AE-10 vs Con
Fold changes Genes Fold changes Genes Fold changes Genes Fold changes Genes
10.7 EIF3S6 10.3 HAND1 10.2 GZMK 10.0 C21orf7
10.7 YLPM1 10.3 CD8B 10.5 CXCR3 10.0 NELL2
16.1 TFCP2L1 10.4 UBASH3A 10.6 AK5 10.4 C21orf7
21.0 SCP2 10.8 TRA@ 10.7 TRA@ 10.4 GFI1B
10.9 TRBV3-1 10.7 IL24 10.5 LOC129293
11.2 CD8B 10.9 CD6 10.5 LOC123876
11.4 MAL 10.9 N/A 10.7 HIST1H3H
11.4 LOC643514 11.2 KIAA0748 11.1 IL24
11.5 NELL2 11.4 LCK 11.4 GFI1B
11.7 TTC24 11.5 CD8B 11.9 CRTAC1
12.7 CD8B 12.3 APBB1 11.9 OR10A4
13.1 LEF1 12.3 IL12RB1 11.9 SAA3P
13.8 TCF7 12.5 TTC24 12.7 TTC24
14.2 LOC129293 12.5 GFI1B 14.9 TFCP2L1
14.5 LOC129293 12.5 CRTAC1 18.6 SCP2
15.6 TCF7 12.6 TRBV3-1 32.3 UNQ470
16.1 TCF7 12.6 ATG9B
16.8 CD8B 12.9 ABLIM1
21.8 TFCP2L1 12.9 LOC129293
25.4 CRTAC1 13.0 CD8B
27.9 SCP2 13.1 CD28














aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).
Wu et al. Critical Care  (2014) 18:508 Page 13 of 27region part, the extracellular matrix, the extracellular
space or the extracellular region (Figure 5C). AECOPD-
specific downregulated genes were involved mainly in the
cell periphery and the plasma membrane and were in-
tegral to the plasma membrane and intrinsic to the
plasma membrane (Figure 5D). In molecular function,COPD-specific upregulated genes participated mainly in
extracellular matrix structural constituent, platelet-derived
growth factor binding, serine-type endopeptidase activity
and protein binding (Figure 6A). COPD-specific downreg-
ulated genes were involved mainly in nucleoside kinase
activity, MHC class II receptor activity, C-acyltransferase
Table 13 Genes downregulated between eight- and tenfold in peripheral blood mononuclear cells of patients with
stable COPD or AECOPD compared to healthy control subjectsa
Stable vs Con AE-1 vs Con AE-3 vs Con AE-10 vs Con
Fold changes Genes Fold changes Genes Fold changes Genes Fold changes Genes
8.2 AK5 8.1 CD3G 8.0 TRBV19 8.1 HFE2
8.6 TRA@ 8.2 LY9 8.0 OTOA 8.2 TRA@
9.1 ZC3HAV1 8.2 AK5 8.1 CD7 8.6 UNQ470
9.3 MAL 8.2 C21orf7 8.1 GRAP2 8.6 CD248
9.7 TMEM50B 8.2 TRBC1 8.1 TNFRSF25 8.6 XG
8.3 ANKDD1A 8.2 C21orf7 8.7 ATG9B
8.4 CD6 8.2 EPHA6 8.8 LOC339778
8.4 RPS6KB1 8.2 GIMAP5 8.9 TCF7
8.5 TMEM50B 8.3 1-Sep 8.9 CCR7
8.7 YLPM1 8.3 UBASH3A 9.2 LOC644663
8.7 TRBV19 8.4 GIMAP7 9.4 LOC129293
8.8 FLT3LG 8.5 MGC23244 9.5 MGC39606
8.9 N/A 8.6 LOC645852 9.7 GZMK
9.1 LEF1 8.7 SCAP1 9.9 AK5
9.1 GZMK 9.0 HIST1H3H 9.9 TCF7
9.1 KIAA0748 9.0 HFE2
9.2 ABLIM1 9.2 GFI1B
9.5 C21orf7 9.2 TMEM50B
9.5 ATG9B 9.5 N/A
9.6 LCK 9.5 C21orf7
9.6 LOC647353 9.6 GATA3
9.8 CCR7 9.7 C21orf7
9.8 UNQ470 9.7 CD247
9.9 OR10A4 9.8 LCK






aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).
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specific upregulated genes were involved mainly in protein
binding, growth factor binding, calcium ion binding
and polysaccharide binding (Figure 6C). AECOPD-specific
downregulated genes were involved mainly in receptor
activity, signaling receptor activity, molecular transducer
activity and signal transducer activity (Figure 6D).
COPD-specific upregulated genes also participated
in extracellular matrix receptor interaction, protein
digestion and absorption, focal adhesion and the phos-
phatidylinositol 3-kinase-Akt signaling pathway (Figure 7A).
AECOPD-specific upregulated genes participated in Chagasdisease, complement and coagulation cascades, per-
tussis and Staphylococcus aureus infection (Figure 7B).
AECOPD-specific downregulated genes participated in
antigen processing and presentation, natural killer cell–
mediated cytotoxicity, graft-versus-host disease and
thyroid cancer (Figure 7C).
Discussion
PBMCs play a critical and important role in the occurrence
of AECOPD, owing to less capacity for balancing the
proinflammatory immune response caused by infection
and for secreting adequate amounts of anti-inflammatory
Table 14 Genes downregulated between six- and eightfold in peripheral blood mononuclear cells of patients with
stable COPD or AECOPD compared to healthy control subjectsa
Stable vs Con AE-1 vs Con AE-3 vs Con AE-10 vs Con
Fold changes Genes Fold changes Genes Fold changes Genes Fold changes Genes
6.0 NDUFV3 6.0 MAL 6.0 IL7R 6.0 HKDC1
6.0 C17orf45 6.0 ARHGAP12 6.0 CD28 6.1 TANC2
6.1 MAL 6.0 TRAPPC4 6.0 KIR2DS1 6.1 FAM5B
6.1 CXCR6 6.0 GNLY 6.0 FLJ20647 6.2 KIAA0748
6.1 SUCLA2 6.0 N/A 6.1 N/A 6.3 CD40LG
6.1 C21orf7 6.0 LOC642376 6.1 CLDN1 6.3 PCDH10
6.2 TNPO1 6.0 MYOZ3 6.1 TRBV5-4 6.3 LOC644273
6.2 LOC643514 6.1 FLJ20647 6.1 CARD11 6.3 CD96
6.2 ALS2CR13 6.1 CD96 6.1 LOC441320 6.3 TRA@
6.2 CREB1 6.2 MAL 6.1 ACADSB 6.3 TRBV3-1
6.2 C17orf45 6.2 GIMAP5 6.1 NXPH4 6.4 TRA@
6.3 NELL2 6.2 CLDN1 6.2 SCNN1D 6.4 LOC642483
6.3 C6orf32 6.2 CD3D 6.2 MTMR1 6.5 ANKDD1A
6.3 LOC642455 6.2 LY9 6.2 MAL 6.5 N/A
6.4 GMDS 6.3 LOC123876 6.2 ZAP70 6.5 N/A
6.4 ABHD6 6.3 TNFRSF25 6.3 MAL 6.5 LY9
6.4 DAPP1 6.3 C21orf7 6.3 IL2RB 6.6 CD8B
6.4 SH3BGRL 6.3 LOC645885 6.3 EDG8 6.6 MGC26597
6.5 IL7R 6.3 BLOC1S3 6.3 HKDC1 6.7 TRBV19
6.6 LOC441601 6.3 LOC644727 6.3 SCAP1 6.7 LOC145783
6.6 GPR18 6.4 CCDC45 6.3 LOC440455 6.8 CD8B
6.7 P2RX5 6.4 C21orf7 6.3 CD300E 6.9 C21orf7
6.7 LY9 6.5 CD28 6.4 LY9 6.9 UBASH3A
6.8 GGPS1 6.5 LOC440455 6.4 KIR2DS2 7.0 LOC400768
6.8 EIF3S6 6.5 IL24 6.4 SLAMF6 7.1 CD8B
6.8 ARHGAP15 6.5 GHRL 6.4 SAA3P 7.1 HAND1
6.8 SF3B1 6.5 FAM113B 6.4 SF3A2 7.2 LOC126075
6.8 GPR89A 6.5 LOC644663 6.5 UNQ470 7.2 TNFRSF7
6.9 LOC129293 6.5 C15orf37 6.5 C6orf21 7.3 LEF1
6.9 CPNE3 6.5 MAL 6.6 CD96 7.3 HLA-DOA
6.9 LY9 6.5 LOC644445 6.6 CD244 7.4 LOC646279
7.0 PIP3-E 6.6 LOC126075 6.6 N/A 7.4 YLPM1
7.0 TAF9 6.6 1-Sep 6.6 KLRK1 7.4 LOC643514
7.0 N/A 6.6 UBASH3A 6.6 C16orf5 7.5 MTMR1
7.0 KIAA0748 6.7 SAA3P 6.6 TRBC1 7.6 NOG
7.1 CD55 6.8 CD6 6.6 LOC339778 7.7 TCF7
7.2 EIF3S6 6.8 TRBV5-4 6.7 GNLY 7.7 KIAA0748
7.2 PGRMC2 6.9 1-Sep 6.7 LDLRAP1 7.7 C21orf7
7.3 C21orf7 6.9 LOC129293 6.8 HAND1 7.7 PRDM9
7.4 PSMD6 7.0 SCNN1D 6.8 CD3D 7.7 FCER2
7.5 ABLIM1 7.0 SIT1 6.8 FLJ45825 7.9 CD8B
7.6 STAG2 7.1 GATA3 6.8 SF3A2 8.0 LEF1
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Table 14 Genes downregulated between six- and eightfold in peripheral blood mononuclear cells of patients with
stable COPD or AECOPD compared to healthy control subjectsa (Continued)
7.8 CCDC45 7.1 CD7 6.8 CXCR3
7.8 UNQ470 7.1 CDKN3 6.8 KIR3DL3
7.9 LY9 7.2 SCAP1 6.8 LAT
8.0 CD40LG 7.3 TRA@ 6.9 CD52
7.3 LY9 6.9 TNFRSF7
7.3 DDAH1 6.9 LOC442726
7.3 TRA@ 6.9 3-Sep
7.5 TNFRSF7 6.9 KIAA0748
7.5 KIAA0748 6.9 XG
7.6 ITM2A 6.9 KIAA1549
7.6 CD5 7.0 RNF157
7.6 D4S234E 7.0 SIT1
7.6 CD300E 7.0 CD1C
7.7 APBB1 7.0 SLC16A10
7.8 CD3D 7.0 CD3G
7.8 LCK 7.1 CD6
7.8 UBASH3A 7.1 LY9

























aData are from patients with stable chronic obstructive pulmonary disease (Stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital admission, as compared to healthy controls (Con).
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Table 15 Genes downregulated more than fivefold in
peripheral blood mononuclear cells of patients with
AECOPD compared to patients with stable COPDa








5.0 PRODH 10.2 KSP37 10.1 LOC646781
5.1 MT1F 10.3 DUB3 10.1 LOC389634
5.1 OR2A7 10.6 DUB3 10.1 LOC441056
5.3 CD8B 10.8 TCF7 10.1 LOC340243
5.4 CGI-38 11.2 CX3CR1 10.2 C1QL2
5.4 DMBT1 17.6 MGC35295 10.2 LOC653541
5.4 N/A 19.9 STAC2 10.2 LOC158318
5.4 GNLY 25.0 AZGP1 10.3 N/A
5.5 LCK 10.4 LOC644373
5.5 DZIP1 10.6 SPDEF
5.6 TCF7 10.7 DUX1
5.6 MGC45438 10.9 LOC643001
5.6 UNQ470 11.1 LOC391767
5.8 MGLL 11.2 LOC645509
5.8 B4GALNT3 11.7 FLJ36131
5.9 CGI-38 11.8 LOC441323
5.9 CGI-38 11.9 LOC440015
6.1 LOC388886 11.9 LOC441812
6.1 GNLY 12.0 TCEB3C
6.2 N/A 12.1 SPDEF
6.4 CD8B 12.3 DUX4
6.4 AEBP2 12.5 LOC285697
6.4 EDG8 12.9 LOC646066
6.5 PRDM16 13.3 LOC441873
6.8 CX3CR1 13.6 LOC645402
7.0 MGC45438 13.7 LOC285563
7.3 MST1 13.9 LOC391763
7.4 LOC644088 14.4 DUB3
7.5 EDG8 14.7 LOC391766
10.1 MGC45438 15.0 LOC392197
12.6 MGC35295 15.0 REXO1L2P
15.5 STAC2 15.2 DUB3









Table 15 Genes downregulated more than fivefold in
peripheral blood mononuclear cells of patients with










aData are from patients acute exacerbation of chronic obstructive pulmonary
disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the hospital
admission, as compared to patients with stable chronic obstructive pulmonary
disease (Stable).
Wu et al. Critical Care  (2014) 18:508 Page 17 of 27cytokines [22]. The fact that patients with COPD are more
susceptible to acute exacerbation has been suggested
to be associated with PBMC dysfunction and failure
of adaptation to infection, stimuli or hypoxia, although
there have been not yet studies on the phenotypes of
PBMCs in AECOPD. For example, PBMCs from patients
with COPD could not induce hypoxia-inducible factor
1 and vascular endothelial growth factor, owing to a
reduction in histone deacetylase 7 under hypoxic con-
dition [23]. It was suggested that overproduction of
proinflammatory cytokines (CXCL6 and interleukin 6
(IL-6)) from human PBMCs could be stimulated by
the infection through activation of Toll-like receptor 4,
nicotinamide adenine dinucleotide phosphate oxidase
phosphatidylinositol 3-kinase and nuclear factor κB [24],
at least as partial mechanisms by which PBMCs may be
involved in the occurrence of AECOPD. The present
study provides initial evidence that dynamic alterations of
PBMC genetic phenotypes occurred in patients with
AECOPD after their hospital admission and during their
hospital stay.
Gene expression profiles of PBMCs were investigated
in patients with COPD, compared with healthy controls
and correlated with lung function measurement [12].
Differential expression of 45 known genes was identified,
of which 16 markers had significant correlation with
quantitative traits and differential expression between
cases and controls and 2 genes, RP9 and NAPE-PLD,
were identified as decreased in patients with COPD, as
compared to controls, in both lung tissue and blood.
Gene expression profiles of PBMCs were recently
identified and validated in smokers with and without
COPD and corrected with clinical phenotypes such as
sex, age, body mass index, family history, smoking status
and pack-years of smoking [25]. Of them, 16 candidate
genes were found to be associated with airflow obstruction
Table 16 Genes downregulated more than fivefold in
peripheral blood mononuclear cells of patients with
AECOPDa








5.0 ITGB3 10.2 MPO 10.3 MOXD1
5.1 CGI-69 10.4 LOC653492 10.3 LOC152573
5.2 SPTB 10.5 SPP1 10.7 SPDEF
5.2 BCL2L1 10.6 ANK1 10.8 CCDC80
5.2 GATA1 11.0 DEFA4 11.0 CTSG
5.3 FBXO7 11.0 MOXD1 11.0 CAMP
5.6 SELENBP1 11.0 HIG2 11.3 PLA2G2D
5.8 OSBP2 11.1 OSBP2 11.4 SPP1
5.9 LOC643855 11.2 REXO1L3P 11.6 S100P
6.1 ERAF 11.6 SPDEF 11.7 SLC4A11
6.2 EPB49 12.0 COL1A1 11.8 COL3A1
6.2 MYH9 12.2 BPI 11.8 SPAG4
6.4 ALAS2 12.3 SNCA 12.5 THBS2
7.4 LOC644462 12.3 SLC4A11 12.7 MPO
7.8 GMPR 12.5 COL1A1 13.0 PRTN3
8.1 ANK1 12.6 AZU1 13.2 COL1A1
8.9 BPGM 12.6 ARG1 13.3 ELA2
9.1 FAM46C 13.2 GREM1 14.3 LIF
9.2 LOC643497 13.5 DEFA4 14.4 CEACAM5
9.4 TRIM58 13.5 ELA2 14.6 RNF183
9.4 MBNL3 14.2 CEACAM5 14.9 B3Gn-T6
9.5 EPB49 14.5 ITGA11 15.1 AZU1
9.6 EPB49 15.0 CEACAM8 15.4 ITGA11
9.6 EPB42 15.3 SPTB 15.9 DEFA4
9.7 EPB41 15.6 CEACAM5 16.4 CEACAM5
9.7 SLC14A1 16.6 LIF 17.5 MS4A3
9.9 EPB42 17.1 TRIM58 17.8 ARG1
10.1 SNCA 19.2 THY1 20.4 THY1
13.5 TRIM58 19.5 MS4A3 21.1 MS4A3
19.7 SLC4A1 23.1 TRIM58 22.5 SPP1
20.7 EPB41 24.1 MS4A3 34.4 SFRP2
21.6 CA1 27.1 SFRP2 49.9 PLUNC
29.9 EPB42 57.1 CALCA
30.4 SPP1 68.9 CALCA
41.9 ALAS2 80.4 BPIL1





Table 16 Genes downregulated more than fivefold in





aData are from patients with acute exacerbation of chronic obstructive
pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) after the
hospital admission.
Wu et al. Critical Care  (2014) 18:508 Page 18 of 27and secondary clinical phenotypes, 12 with emphysema,
13 with gas trapping and 8 with distance walked. Both
previous studies demonstrated the gene expression
profiles of PBMCs from patients with stable COPD
and addressed the potential significance of smoking.
In the present study, we selected healthy control subjects
and patients who were not current smokers and demon-
strated gene expression profiles of PBMCs from patients
with COPD, including stable COPD and AECOPD. We
addressed COPD-specific gene expression profiles that
should appear in both stable COPD and COPD exacerba-
tion conditions and found COPD-specific 79 genes were
upregulated and 23 genes down-regulated more than five-
fold as compared with gene expression in controls. In the
present study, we selected consistent up- or downregu-
lated gene expression on days 1, 3 and 10 of AECOPD-
specific as compared with gene expression in both
healthy controls and patients with stable COPD, as
AECOPD-specific gene expression profiles. We found that
58 AECOPD-specific genes were upregulated more
than fivefold and 238 genes were downregulated more
than twofold, as compared to both control subjects and
patients with stable COPD.
Variation of gene expression profiles is dependent upon
multiple uncontrollable factors, such as study population,
age, history, genetic background and treatment. In
addition, gene expression profiles vary between harvested
sample types, such as sputum, bronchoalveolar lavage
fluid, blood or lung tissues. For example, 102 genes were
identified to distinguish between non- or mild emphysema
and severe emphysema in lung tissue [15] and to distin-
guish 70 microRNAs and 2,667 mRNAs between smoking
patients with or without COPD [26]. In the present study,
we investigated gene expression profiles of PBMCs from
control subjects, patients with stable COPD, and patients
with AECOPD on day 1, day 3 and day 10 of hospital
admission, and we found about 3,000 overexpressed genes
and 2,000 downregulated genes in patients with stable
COPD or AECOPD, as compared with control subjects.
These findings indicate that those COPD-specific genes
exist in the stable COPD condition and during acute
exacerbations of COPD.
Of the COPD-specific genes we studied, CEACAM1,
COL6A3, NOL3, COL1A2, MLPH, MUC1, P8, UNQ473,
Table 17 Number and details of co–differentially up- or downregulated genes in peripheral blood mononuclear cells of
patients with stable COPD or AECOPD compared to healthy control subjectsa














D12502 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 10.1 83.0 66.5 10.5
NM_004369 COL6A3 Collagen, type VI, α3 10.4 21.0 22.4 10.8
AF064599 NOL3 Nucleolar protein 3 (apoptosis repressor with CARD domain) 12.1 13.6 16.3 11.5
BC042586 COL1A2 Collagen, type I, α2 13.1 72.3 92.9 17.2
BC014473 CEACAM1 Carcinoembryonic antigen-related cell adhesion molecule 1 14.7 101.2 61.0 11.8
AY358857 MLPH Melanophilin 17.0 10.3 12.8 12.2
AF348143 MUC1 Mucin 1, cell surface-associated 20.0 19.7 20.1 28.6
NM_012385 P8 p8 protein (candidate of metastasis 1) 20.1 19.1 21.3 22.1
BC093946 UNQ473 DMC 20.2 45.9 53.1 24.3
NM_001305 CLDN4 Claudin 4 23.0 34.4 39.1 20.7
NM_002933 RNASE1 Ribonuclease, RNase A family, 1 (pancreatic) 26.9 12.5 15.2 37.2
BC053636 H19 H19, imprinted maternally expressed untranslated mRNA 29.5 37.2 28.0 11.8
BC069423 DEFA1 Defensin, α1 33.0 96.1 86.7 10.2
XM_928349 LOC653600 Similar to neutrophil defensin 1 precursor (HNP-1)
(HP-1) (HP1) (defensin, α1)












M38056 HLA-DOA Major histocompatibility complex, class II, DOα 5.3 5.9 5.6 7.3
AY209188 SAA3P Serum amyloid A3 pseudogene 5.3 6.7 6.4 11.9
BC069511 UBASH3A Ubiquitin-associated and SH3 domain-containing, A 5.5 10.4 14.3 6.9
AJ421515 CRTAC1 Cartilage acidic protein 1 5.6 25.4 12.5 11.9
AL133666 EPHA6 EPH receptor A6 5.6 5.8 8.2 5.3
NM_020152 C21orf7 Chromosome 21 open reading frame 7 5.7 8.2 9.7 10.4
XM_089384 TTC24 Tetratricopeptide repeat domain 24 5.8 11.7 12.5 12.7
NM_006850 IL24 Interleukin 24 6.0 6.5 10.7 11.1
AL713701 C21orf7 Chromosome 21 open reading frame 7 6.1 9.5 9.5 10.0
XM_931594 LOC643514 Hypothetical protein LOC643514 6.2 11.4 5.7 7.4
NM_006159 NELL2 NEL-like 2 (chicken) 6.3 11.5 7.3 10.0
NM_002348 LY9 Lymphocyte antigen 9 6.7 8.2 7.4 6.5
XM_934852 LOC129293 Hypothetical protein LOC129293 6.9 14.5 12.9 9.4
BC062589 LY9 Lymphocyte antigen 9 6.9 7.3 7.1 5.5
XM_934149 KIAA0748 KIAA0748 7.0 7.5 11.2 6.2
BC008567 C21orf7 Chromosome 21 open reading frame 7 7.3 6.3 7.5 7.7
NM_138363 CCDC45 Coiled-coil domain containing 45 7.8 6.4 5.9 5.2
BC022101 UNQ470 GAAI470 7.8 44.1 18.1 32.3
BC027920 LY9 Lymphocyte antigen 9 7.9 6.2 5.8 5.3
BC033896 AK5 Adenylate kinase 5 8.2 8.2 10.6 9.9
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Table 17 Number and details of co–differentially up- or downregulated genes in peripheral blood mononuclear cells of
patients with stable COPD or AECOPD compared to healthy control subjectsa (Continued)
XM_085151 YLPM1 YLP motif containing 1 10.7 8.7 5.1 7.4
NM_014553 TFCP2L1 Transcription factor CP2-like 1 16.1 21.8 32.0 14.9
NM_001007098 SCP2 Sterol carrier protein 2 21.0 27.9 18.7 18.6
aData are from patients with stable chronic obstructive pulmonary disease (stable) or acute exacerbation of chronic obstructive pulmonary disease on day 1
(AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as compared to healthy controls (Con).
Wu et al. Critical Care  (2014) 18:508 Page 20 of 27CLDN4, RNASE1, H19, DEFA1 and LOC653600 were
upregulated more than tenfold, mainly related to nuclear
proteins, collagens or molecular structure. We noted
that transcription factor CP2 (TFCP2L1) and SCP2 were
downregulated more than tenfold. In previous studies,
these genes, including CEACAM1, TFCP2L1 and SCP2,
were not found to be associated with COPD. The SCP2
gene is located within chromosome 1 and encodes
the nonspecific lipid transfer protein SCP2, which is
involved in organellar fatty acid metabolism [27,28]
and the translocation of cytoplasmic free cholesterolTable 18 Number of co–differentially up- or downregulated g





Selected co–differentially upregulated genes (>10-fold)
SEQ_ID Gene name AE-1
AE-1 vs Con AE-1 vs Stable A
BC004490 FOS 27.4 28.6 3
BC015492 IFI27 12.3 10.3 1
NM_001554 CYR61 12.0 40.3 1
NM_001901 CTGF 35.7 26.6 3
NM_003979 GPRC5A 21.2 12.6 1
NM_006732 FOSB 21.7 13.7 4
NM_133504 DCN 19.0 17.2 1
XM_373497 LOC387763 41.4 13.5 4
Selected co–differentially downregulated genes (>3-fold)
SEQ_ID Gene names AE-1
AE-1 vs Con AE-1 vs Stable A
AJ002102 KIR2DS2 3.7 3.8 7
BC022407 SH2D1B 3.0 3.7 4
BC066595 SH2D1B 3.6 3.2 9
BC100911 CD8B 11.2 4.4 1
NM_001004698 OR2W5 3.7 3.1 4
NM_004931 CD8B 10.3 5.3 1
NM_031950 KSP37 4.8 5.0 9
NM_201633 TCF7 15.6 5.6 3
aData are from acute exacerbation of chronic obstructive pulmonary disease on day
compared to patients with stable COPD (Stable) or healthy controls (Con).to the mitochondria [29]. Our results indicate that
PBMCs from patients with stable COPD or AECOPD
had downregulated SCP2, which might point to severe
metabolic disorder and thus that SCP2 downregulation
might contribute to one of the common comorbidities
of COPD [30]. TFCP2 is a member of a family of
transcription factors that regulate genes involved in
events from early development to terminal differentiation
[31]. PBMCs with downregulated TFCP2 of patients with
COPD might have less capacity of the transcriptional







E-3 vs Con AE-3 vs Stable AE-10 vs Con AE-10 vs Stable
3.5 34.9 13.2 13.7
3.1 11.0 21.6 18.1
1.2 37.6 11.7 39.2
6.9 27.5 59.3 44.2
9.2 11.4 75.8 45.1
0.1 25.3 35.6 22.5
9.6 17.8 20.0 18.1
6.4 15.2 41.3 13.5
AE-3 AE-10
E-3 vs Con AE-3 vs Stable AE-10 vs Con AE-10 vs Stable
.4 7.6 4.2 4.4
.8 5.9 3.1 3.8
.9 8.9 3.6 3.2
6.0 6.3 7.9 3.1
.7 4.0 3.7 3.1
1.5 5.9 6.6 3.4
.8 10.2 3.0 3.1
0.4 10.8 8.9 3.2
1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission, as
Table 19 Number of genes in peripheral blood mononuclear cells of patients with AECOPDa
Down–down Down–up Up–down Up–up
Total 353 784 1,005 127
>2-fold 52 131 238 8
>4-fold 3 3 7 0
>5-fold 2 0 0 0
Selected co–differentially expressed genes at the down–down pattern (>4-fold)
SEQ-ID Gene name Full name of gene AE-3 vs AE-1 AE-10 vs AE-3
NM_000032 ALAS2 Aminolevulinate, delta-, synthase 2 6.4 6.5
BC099627 EPB42 Erythrocyte membrane protein band 4.2 9.9 4.4
BC027890 CA1 Carbonic anhydrase I 21.6 5.1
Selected co–differentially expressed genes at the down–up pattern (>4-fold)
SEQ-ID Gene name Full name of gene AE-3 vs AE-1 AE-10 vs AE-3
AK127453 N/A Homo sapiens cDNA FLJ45545 fis, clone BRTHA2034281. 4.7 5.7
NM_003944 SELENBP1 Selenium-binding protein 1 5.6 4.1
BC090921 MYH9 Myosin, heavy chain 9, non-muscle 6.2 4.1
Selected co–differentially expressed genes at the up–down pattern (>4-fold)
SEQ-ID Gene name Full name of gene AE-3 vs AE-1 AE-10 vs AE-3
NM_181717 HCG27 HLA complex group 27 4.1 7.3
NM_177551 GPR109A G protein-coupled receptor 109A 4.3 7.5
NM_006018 GPR109B G protein-coupled receptor 109B 4.4 5.1
AF249277 MTHFS 5,10-methenyltetrahydrofolate synthetase
(5-formyltetrahydrofolate cyclo-ligase)
4.6 5.3
AY234180 BCL2A1 BCL2-related protein A1 5.2 4.0
BC010952 PI3 Peptidase inhibitor 3, skin-derived (SKALP) 6.0 4.4
NM_002243 KCNJ15 Potassium inwardly rectifying channel, subfamily J,
member 15
7.0 4.8
Selected co–differentially expressed genes at the up–up pattern (>2-fold)
SEQ-ID Gene name Full name of gene AE-3 vs AE-1 AE-10 vs AE-3
Z15108 PRKCZ Protein kinase C, zeta 2.0 2.8
BC037798 CGI-38 Brain-specific protein 2.0 2.4
NM_001033581 PRKCZ Protein kinase C, zeta 2.1 2.8
NM_007168 ABCA8 ATP-binding cassette, subfamily A, member 8 2.1 4.0
AK022468 SORBS1 Sorbin and SH3 domain containing 1 2.3 3.5
NM_006403 NEDD9 Neural precursor cell expressed, developmentally
downregulated 9
2.3 2.2
NM_023037 FRY Furry homologue (Drosophila) 2.3 2.1
NM_016730 FOLR1 Folate receptor 1 (adult) 3.0 11.7
Down–down GENE_NAME SEQ_ID AE-1 vs Stable AE-3 vs Stable AE-10 vs Stable
ALAS2 NM_000032 17.64 2.76 −2.37
EPB42 BC099627 10.02 1.01 −4.37
CA1 BC027890 103.93 4.81 −1.06
Down–up GENE_NAME SEQ_ID AE-1 vs Stable AE-3 vs Stable AE-10 vs Stable
N/A AK127453 −1.69 −7.90 −1.38
SELENBP1 NM_003944 3.97 −1.41 2.92
MYH9 BC090921 −1.36 −8.40 −2.04
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Table 19 Number of genes in peripheral blood mononuclear cells of patients with AECOPDa (Continued)
Up–down GENE_NAME SEQ_ID AE-1 vs Stable AE-3 vs Stable AE-10 vs Stable
HCG27 NM_181717 1.09 4.47 −1.63
GPR109A NM_177551 4.12 17.79 2.36
GPR109B NM_006018 2.64 11.64 2.28
MTHFS AF249277 4.51 20.75 3.95
BCL2A1 AY234180 2.38 12.45 3.11
PI3 BC010952 1.03 6.20 1.42
KCNJ15 NM_002243 2.25 15.78 3.26
Up–up GENE_NAME SEQ_ID AE-1 vs Stable AE-3 vs Stable AE-10 vs Stable
PRKCZ Z15108 −1.25 1.61 4.46
CGI-38 BC037798 −5.87 −2.86 −1.18
PRKCZ NM_001033581 −1.61 1.30 3.64
ABCA8 NM_007168 −1.27 1.68 6.69
SORBS1 AK022468 1.28 2.92 10.30
NEDD9 NM_006403 2.43 5.57 12.15
FRY NM_023037 −1.11 2.08 4.34
FOLR1 NM_016730 −4.20 −1.39 8.39
aData are from acute exacerbation of chronic obstructive pulmonary disease on day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of the hospital admission.
Comparisons are between AE-1 and AE-3 or between AE-3 and AE-10.
Wu et al. Critical Care  (2014) 18:508 Page 22 of 27viral gene promoters, or interaction with certain inflam-
matory response factors, although the exact mechanism
and pathological role remain unclear.
AECOPD-specific gene expression profiles were selected
by comparing them with both healthy control subjects
and patients with stable COPD, including 647 upregu-
lated genes and 238 downregulated genes (greater
than twofold upregulation). Of them, FOS, IFI27, CYR61,
CTGF, GPRC5A, FOSB, DCN and LOC387763 were
upregulated more than tenfold and KIR2DS2, SH2D1B,
CD8B, OR2W5, KSP37 and TCF7 were downregulated
more than threefold.
We noticed that some genes, such as FOS, CYR61 and
CTGF, were upregulated in PBMCs from patients with
either stable COPD or AECOPD, consistent with the
lung tissue gene expression profiles of patients with
COPD or smokers, in whom the genes were expressed
mainly in alveolar epithelial cells, airway epithelial cells
and stromal and inflammatory cells [14]. Other genes,
including GPRC5A, LOC387763 and KIR2DS2, were
not found to be associated with AECOPD in previous
publications. CTGF is a cysteine-rich peptide implicated
in several biological processes, such as cell proliferation,
survival and migration, and involved in pulmonary
vascular remodeling and hypertension in COPD. It
was evidenced by the experimental finding that CTGF
short-hairpin RNA could significantly prevent CTGF
and cyclin D1 expression, arrest cell cycle at the G0/G1 phase, suppress cell proliferation in smoking-
exposed pulmonary smooth muscle cells and ameliorate
pulmonary vascular remodeling [32]. Another study dem-
onstrated that some inflammatory genes (IL-1β, IL-6, IL-8,
CCL2 and CCL8) were upregulated, whereas some growth
factor receptor genes (BMPR2, CTGF, FGF1, KDR and
TEK) were downregulated in lung tissue samples from pa-
tients who were current smokers or had moderate COPD
[33].
Downregulation of TCF7 was found in PBMCs of
patients with COPD and current smoking and was
correlated with some clinical phenotypes, such as emphy-
sema, gas trapping and distance walked [25]. In the
present study, we also found that TCF7 was downregu-
lated in ex-smokers with COPD by about an absolute
threefold compared with control subjects, and, in patients
with AECOPD, TCF7 was downregulated by about an
absolute tenfold compared with both control subjects
and patients with stable COPD. These findings indi-
cate that TCF7 not only is a COPD-specific gene but
also is associated with the severity of the disease.
TCF7 is a member of a family of HMG box contain-
ing factors associated with β-catenin to mediate Wnt
signaling, controls the switch between cell self-
renewal and differentiation and plays a role in B cell
and T cell development. TCF7 was found to be the
most downregulated transcription factor when CD34+














































































Figure 3 Dynamic patterns of changes of gene expression of peripheral blood monocytes. Consistent decrease (A) or consistent increase
(B), followed by a decrease (C), or a decrease followed by a recovery (D), in patients with acute exacerbation of chronic obstructive pulmonary
disease (AECOPD) at day 1 (AE-1), day 3 (AE-3) and day 10 (AE-10) of hospital admission as compared with changes seen in patients with
stable COPD.
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Figure 4 Gene expression profile comparisons regarding the biological process. Graphs describe co–differentially upregulated genes
(A) and downregulated genes (B) in the biological process of peripheral blood mononuclear cells from patients with chronic obstructive pulmonary
disease (COPD), including those with stable COPD and acute exacerbation of COPD (AECOPD), as compared to healthy control subjects. Also shown
are co–differentially expressed upregulated genes (C) and downregulated genes (D) from patients with AECOPD, as compared to patients with stable
COPD and healthy control subjects.
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Figure 5 Gene expression profile comparisons regarding the cellular component. Graphs describe co–differentially upregulated genes
(A) or downregulated genes (B) in the cellular component of peripheral blood mononuclear cells from patients with chronic obstructive
pulmonary disease (COPD), including stable COPD and acute exacerbation of COPD (AECOPD), as compared to healthy control subjects. Also
shown are co–differentially expressed upregulated genes (C) or downregulated genes (D) from patients with AECOPD, as compared to both
patients with stable COPD and healthy control subjects. MHC, Major histocompatibility complex.
Wu et al. Critical Care  (2014) 18:508 Page 24 of 27regulation of the binding between TCF7 and the short
isoforms of RUNX1 [34]. It is possible the downregu-
lation of TCF7 and associated regulation may be one
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Figure 6 Gene expression profile comparisons regarding molecular fu
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patients with AECOPD were evaluated with dynamic
DESS scores. ALAS2, EPB42 and CA1 were co–differentially
expressed with a down–down type in patients with
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Figure 7 Gene expression profile comparisons regarding signaling pathways. Graphs describe co–differentially upregulated genes (A) in
different pathways of peripheral blood mononuclear cells from patients with chronic obstructive pulmonary disease (COPD), including patients with
stable COPD and acute exacerbation of COPD (AECOPD), as compared to healthy control subjects. Also shown are co–differentially expressed
upregulated genes (B) or downregulated genes (C) from patients with AECOPD, as compared to patients with stable COPD and healthy control
subjects. ECM, Extracellular matrix; MHC, Major histocompatibility complex; Pi3K, Phosphatidylinositol 3-kinase.
Wu et al. Critical Care  (2014) 18:508 Page 25 of 27a protein which is important in respiratory function, fluid
secretion and maintenance of cellular acid–base homeosta-
sis [35]. The genes with a down–up type included
SELENBP1, MYH9 and an unnamed gene in chromosome
19, both of which are associated with psychotic disorders
[36,37]. One limitation of the present study is the small
sample size, which detracts from the generalizability of the
results presented.
Conclusions
Dynamic alterations of PBMC gene expression profiles were
initially investigated in patients with AECOPD, as compared
with healthy control subjects or patients with stable COPD.
A panel of genes, including eight that were upregulated and
eight that were downregulated, were recommended as
AECOPD-specific dynamic biomarkers. AECOPD-specific
up- or downregulated genes in the biological process, cellu-
lar components or molecular function were defined andparticipated in complement and coagulation cascades, infec-
tion, antigen processing and presentation, natural killer
cell–mediated cytotoxicity, and/or cancer-causing potential.
The integration of dynamic bioinformatics with clinical phe-
notypes helped us to identify and validate AECOPD-specific
biomarkers to help define the severity, duration and
response of the disease to therapies.
Key messages
 Circulating dynamic biomarkers were identified for
the specificity and severity of AECOPD.
 A panel of 16 genes were selected as
AECOPD-specific biomarkers.
 This is an initial study designed to examine
gene expression profiles of peripheral blood
mononuclear cells and identify dynamic changes
of AECOPD-specific biomarkers.
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Additional file 1: DESS scores. This file lists Digital Evaluation Score
System (DESS) scores of subjects from each group.
Additional file 2: Eight supplemental figures. Figure S1. A box plot
showing distributions of log2 ratios among groups. They reflect our
assessment of the quality of genetic data after the filtering and
distribution of data sets. Figure S2. Hierarchical clustering shows
distinguishable gene expression profiles and relationships between
different groups. Figure S3. Co–differentially upregulated genes within
10 comparison pairs mainly involved in the biological process. Stable vs
Con (A); AE-1 vs Con (B); AE-3 vs Con (C); AE-10 vs Con (D); AE-1 vs
Stable (E); AE-3 vs Stable (F); AE-10 vs Stable (G); AE-3 vs AE-1 (H); AE-10
vs AE-1 (I); AE-10 vs AE-3 (J). Figure S4. Co–differentially downregulated
genes within 10 comparison pairs mainly involved in the biological
process. Figure S5. Co–differentially upregulated genes within 10
comparison pairs mainly involved in the cellular component. Figure S6.
Co–differentially downregulated genes within 10 comparison pairs
mainly involved in the cellular component. Figure S7. Co–differentially
upregulated genes within 10 comparison pairs mainly involved in the
molecular function. Figure S8. Co–differentially downregulated genes
within 10 comparison pairs mainly involved in the molecular function.
Additional file 3: Differentially expressed genes. This file lists 10
comparison pairs with information of fold changes and regulation,
normalized intensities or annotations.
Additional file 4: Co–differentially expressed genes. This file lists
COPD-specific and AECOPD-specific genes, as well as dynamically
changed genes, in patients with AECOPD.
Additional file 5: Gene Ontology database. This file lists gene
numbers for 10 comparison pairs with certain GO (Gene Ontology) terms
and different enrichment score ranges.
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